A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
By doing this study, our research team would like to learn if using a blood test that
measures the amount of tumor DNA in blood can help guide how we use chemotherapy combined
with immunotherapy for individuals with head and neck cancer. Using this blood test, the
research team hopes to learn if intermittent (occasional) chemotherapy added to immunotherapy
will work better than immunotherapy alone. Your participation in this research will last
about two years.